WO2012077983A2 - Ape1/ref-1을 함유하는 방광암 진단용 조성물, 및 이를 이용한 방광암 진단 키트 - Google Patents
Ape1/ref-1을 함유하는 방광암 진단용 조성물, 및 이를 이용한 방광암 진단 키트 Download PDFInfo
- Publication number
- WO2012077983A2 WO2012077983A2 PCT/KR2011/009446 KR2011009446W WO2012077983A2 WO 2012077983 A2 WO2012077983 A2 WO 2012077983A2 KR 2011009446 W KR2011009446 W KR 2011009446W WO 2012077983 A2 WO2012077983 A2 WO 2012077983A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ref
- ape1
- bladder cancer
- antibody
- serum
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Definitions
- the present invention relates to a composition for diagnosing bladder cancer containing APE1 / Ref-1, and a bladder cancer diagnostic kit using the same.
- Bladder cancer is the most common cancer of the urinary system, and its cause is relatively high. It is known to cause cancer by stimulating the bladder wall as smoking and various chemicals (for example, dyes such as leather, air pollutants, artificial sweeteners and nitrates) are absorbed into the body and excreted in the urine. .
- various chemicals for example, dyes such as leather, air pollutants, artificial sweeteners and nitrates
- cystoscopy in which a catheter (conduit) is pushed into the bladder to remove and examine a suspected tissue, is a relatively invasive method.
- bladder cancer diagnosis method is to use a method to cut a part of the body, it is difficult to diagnose bladder cancer early.
- Bladder cancers are classified as superficial or invasive cancers according to the involvement of the bladder muscle layer. On average, about 30% of patients are invasive bladder cancers. Therefore, early diagnosis is best when the extent of the lesion is small in order to increase the survival of the patient. Therefore, there is an urgent need for development of a more effective diagnostic method, namely, early diagnosis, treatment of a large-capacity sample, and high sensitivity and specificity of a bladder cancer-specific biomarker.
- APE1 / Ref-1 (apurinic / apyrimidinic endonuclease1 / redox factor-1) is a multifunctional protein consisting of 318 amino acids including a redox region and a DNA repair region. This protein is known to have the ability of APE1 to repair the site of DNA damage and the redox function of transcription factors such as AP-1 and NF-kB (Gurusamy, Malik et al. 2007). APE1 / Ref-1's transcription factor reductive regulation plays a role in facilitating transcription by reducing oxidized cysteine residues in the DNA binding regions of several transcription factors (Xanthoudakis, Miao et al. 1994; Tell, Damante et al. 2005).
- APE1 / Ref-1 is present in all cells and tissues, and intracellular expression sites are known to vary from cell to cell. Expression regulation of APE1 / Ref-1 is regulated at the transcriptional and post-transcriptional levels. The main cause of increased expression of APE1 / Ref-1 is reactive oxygen species (ROS). Treatment of hydrogen peroxide and hypochlorous acid (HOCl) in macrophages and lymphocytes increases the expression of APE1 / Ref-1 intracellularly, and this increase in expression of APE1 / Ref-1 is associated with cellular toxicity and oxidative damage. It is thought to be an adaptive response of cells for protection (Ramana, Boldogh et al. 1998).
- ROS reactive oxygen species
- a nuclear localization signal is present at the amino acid terminus of APE1 / Ref-1 (Jackson, Theriot et al. 2005), and nitrification of amino acids cysteine 93 and 310 results in APE1 / Ref- in the nucleus. It is known that there is a nuclear export signal (NES) that transfers 1 to the cytoplasm (Qu, Liu et al. 2007).
- NES nuclear export signal
- APE1 / Ref-1 protein produced intracellularly may be released extracellularly.
- the endothelial cell activity and inflammatory response in macrophages liberate APE1 / Ref-1 extracellularly.
- the ability to accurately measure APE1 / Ref-1 is believed to be important in understanding the potential role of APE1 / Ref-1 in many biological processes such as cardiocerebrovascular disease, infectious disease and tumors.
- APE1 / Ref-1 protein acts as a diagnostic marker for bladder cancer, and there is no research on this. Therefore, there is an urgent need for the development of biomarkers that can increase the survival rate of patients by early diagnosis of bladder cancer in the blood at the time of health examination.
- the present inventors are studying biomarkers that can quickly and easily diagnose bladder cancer early, and the concentration of APE1 / Ref-1 protein is higher in the bladder cancer patients than in normal human serum, especially in the patients with bladder cancer. Significantly increased in and increased in the serum of bladder cancer patients regardless of the number of relapses, and completed the present invention.
- the present invention is to provide a composition for diagnosing bladder cancer containing APE1 / Ref-1.
- the present invention also provides a bladder cancer diagnostic kit containing an antibody that specifically binds to APE1 / Ref-1.
- the present invention is to provide a method for measuring the concentration of APE1 / Ref-1 in a biological sample through an antigen-antibody binding reaction using an antibody that specifically binds to bladder cancer marker APE1 / Ref-1.
- the concentration of APE1 / Ref-1 of the present invention is significantly increased in the serum of bladder cancer patients, particularly in the serum of two or more bladder cancer patients, than in the serum of normal persons.
- the concentration of APE1 / Ref-1 protein in the serum of bladder cancer patients is significantly increased than in the serum of early bladder cancer patients, regardless of the recurrence. Therefore, the APE1 / Ref-1 protein of the present invention can predict the diagnosis or prognosis of bladder cancer early, and thus can be usefully used as a marker for bladder cancer diagnosis.
- FIG. 1 is a diagram showing an ELISA standard curve of APE1 / Ref-1 protein.
- FIG. 2 is a diagram comparing the concentration of APE1 / Ref-1 protein in the serum of bladder cancer patients and normal subjects by sandwich ELISA.
- FIG. 3 is a diagram showing the concentration of APE1 / Ref-1 protein in the serum of bladder cancer patients according to the stages of bladder cancer.
- Figure 4 is a diagram showing the concentration of APE1 / Ref-1 protein in the serum of bladder cancer patients according to the recurrence frequency and pathological variables of bladder cancer [(A) R 0 : does not relapse, R 1 : 1 relapse, R 3 : 3 relapses, R 7 : 7 relapses; (B) single: single, multiple: multiple].
- the present invention provides a composition for diagnosing bladder cancer containing APE1 / Ref-1.
- the present invention also provides a bladder cancer diagnostic kit containing an antibody that specifically binds to APE1 / Ref-1.
- the present invention also provides a method for measuring the concentration of APE1 / Ref-1 in a biological sample through an antigen-antibody binding reaction using an antibody that specifically binds to the bladder cancer marker APE1 / Ref-1.
- the concentration of APE1 / Ref-1 protein of the present invention is increased 1.5-3.5 times higher in the serum of bladder cancer patients than in the serum of normal subjects, and the higher the stage of bladder cancer, especially in the serum of two or more bladder cancer patients. .
- the concentration of APE1 / Ref-1 protein in the serum of bladder cancer patients is significantly increased than in the serum of early bladder cancer patients, regardless of the recurrence. Therefore, the APE1 / Ref-1 protein of the present invention can predict the diagnosis or prognosis of bladder cancer early, and thus can be usefully used as a marker for bladder cancer diagnosis.
- a bladder cancer diagnostic kit comprising an antibody that specifically binds to APE1 / Ref-1 of the present invention may be easily prepared by a manufacturing method commonly used in the art using the APE1 / Ref-1 protein. Can be.
- the bladder cancer diagnostic kit includes an antibody specifically binding to APE1 / Ref-1, a secondary antibody conjugate conjugated with a label developed by reaction with a substrate, a color substrate solution to react with the developed label, and a wash. Solution and enzymatic stop solution, and the like.
- the label of the secondary antibody conjugate is preferably a conventional coloring agent that performs a color reaction. isothiocyanate, fluorescent materials such as rhodamine-B-isothiocyanate (RITC), dyes, and the like.
- the chromogenic substrate solution is preferably used according to the label, TMB (3,3 ', 5,5'-tetramethyl bezidine), ABTS [2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid )], OPD (o-phenylenediamine) and the like can be used.
- the color development substrate is more preferably provided in a dissolved state in a buffer solution (0.1M NaOAc, pH 5.5).
- the wash solution preferably comprises phosphate buffer, NaCl and Tween 20, more preferably a buffer consisting of 0.02M phosphate buffer, 0.13M NaCl, and 0.05% Tween 20 (PBST).
- PBST 0.05% Tween 20
- the washing solution is reacted with the secondary antibody to the antigen-antibody conjugate, and then washed 3 to 6 times by adding an appropriate amount to the fixed body.
- sulfuric acid solution may be used as the reaction terminating solution.
- the present invention measures the concentration of APE1 / Ref-1 protein in a biological sample through an antigen-antibody binding reaction using an antibody that specifically binds to bladder cancer marker APE1 / Ref-1, thereby diagnosing or prognostic bladder cancer It can be predicted early.
- the biological sample is contacted with a capture antibody immobilized on a fixed body, the remaining sample is separated from the immobilized capture antibody, and the immobilized capture antibody-target molecular complex is contacted with a detection antibody.
- the concentration of APE1 / Ref-1 protein in the biological sample is then measured using a detection method that can recognize the detection antibody.
- the concentration of APE1 / Ref-1 in the serum of bladder cancer patients is higher than in the serum of normal people, it is diagnosed as having bladder cancer or having bladder cancer To predict.
- the concentration of APE1 / Ref-1 protein increases significantly as the stage of bladder cancer increases, preferably in the serum of two or more stages of bladder cancer patients.
- the biological sample may include, but is not limited to, a sample such as tissue, cells, whole blood, serum, plasma, saliva, sputum, and urine obtained from a mammal.
- the sample may be pretreated by filtration, distillation, extraction, concentration, inactivation of interference components, addition of reagents, etc. before use.
- a nitrocellulose membrane As the fixture for the antigen-antibody coupling reaction, a nitrocellulose membrane, a polyvinylidene difluoride membrane (PVDF) membrane, a 96 well plate synthesized with a polyvinyl resin or polystyrene resin, a glass slide glass, or the like may be used.
- PVDF polyvinylidene difluoride membrane
- the antigen-antibody binding reaction is conventional enzyme immunoassay (ELISA), radioimmunoassay (RIIA), sandwich ELISA method, Western blotting, immunoprecipitation method, immunohistochemical staining (immmhihistochemical staining), fluid cytometry ( flow cytometry), fluorescence activated cell sorting (FACS), enzymatic substrate coloration, and antigen-antibody aggregation.
- ELISA enzyme immunoassay
- RAIA radioimmunoassay
- sandwich ELISA method Western blotting
- immunoprecipitation method immunohistochemical staining
- fluid cytometry flow cytometry
- FACS fluorescence activated cell sorting
- enzymatic substrate coloration antigen-antibody aggregation.
- the antibody may be a whole form of an antibody (hereinafter referred to as “antibody”) or a functional fragment thereof.
- the whole antibody may be in the form of a monomer or a multimer having two or more whole antibodies bound thereto.
- the functional fragment of the antibody is an antibody having the heavy and light chain variable regions of the whole antibody, which means to recognize the same antigen binding site (epitope) that the whole antibody recognizes.
- Functional fragments of the antibody include, but are not limited to, single chain variable region fragments (scFv), (scFv) 2 , Fab, Fab 'and F (ab') 2 , and the like.
- the single chain variable region (scFv) refers to an antibody fragment in which a heavy chain variable region and a light chain variable region are linked through a linker peptide to take the form of a single chain polypeptide.
- the antibody can be modified by binding to various molecules such as enzymes, fluorescent materials, radioactive materials and proteins. Modified antibodies can be obtained by chemically modifying the antibody. Such modification methods are commonly used in the art.
- the antibody is obtained as a chimeric antibody in which a variable region derived from a non-human antibody and a constant region derived from a human antibody are combined, or complementarity derived from a non-human antibody. It may be obtained as a humanized antibody in which a constant region is combined with a frame work region (FR) derived from a human antibody including a crystal site.
- FR frame work region
- Example 1 Determination of APE1 / Ref-1 Protein Concentration in Serum of Bladder Cancer Patients
- APE1 / Ref-1 in serum of bladder cancer patients and normal subjects blood from normal and bladder cancer patients was collected using whole blood collection tubes containing anticoagulants. About 10 ml of blood were collected from 51 patients with bladder cancer and 56 patients with normal medical examination. The collected blood was left to shake at room temperature and then centrifuged at 2500 rpm for 10 minutes to separate supernatant (ie, plasma). The separated supernatant was stored at 4 ° C. at low temperature and then 100 ⁇ l per sample was used for sandwich ELSIA.
- Anti-APE1 / Ref-1 polyclonal antibody (Abcam, ab64865) was used as a capture antibody recognizing APE1 / Ref-1.
- Anti-APE1 / Ref-1 monoclonal antibody (Abcam, ab194) was used as a detection antibody that recognizes APE1 / Ref-1 bound to the capture antibody.
- As a labeling material of APE1 / Ref-1 the recombinant human APE1 / Ref-1-His isolated and purified from E. coli was successively diluted 5-fold (0-25ng).
- Capture antibodies in coating buffer were diluted to a concentration of 200 ng / ml and coated on 96-well microliter plates (BD Falcon 3072, Franklin, NJ) for ELISA. Plates were coated overnight at 4 ° C. To remove unbound APE1 / Ref-1 polyclonal antibody, plates were washed three times with wash solution (PBS, 0.05% Tween 20). After washing, the plate was blocked with 250 ⁇ l of blocking solution (PBS, 5% Bovine Serum Albumin, BSA) at room temperature for 1 hour. 100 ⁇ l of plasma samples from bladder cancer patients and normal subjects were added to 96-well plates, respectively, and reacted at 37 ° C. for 90 minutes.
- coating buffer 0.5 M sodium hydrogen carbonate buffer, pH 9.6
- the plate was washed five times with washing solution.
- the detection antibody anti-APE1 / Ref-1 monoclonal antibody was diluted to a concentration of 200 ng / ml and reacted at room temperature for 2 hours. Plates were washed seven times with wash solution.
- HRP-conjugated anti-mouse IgG secondary antibody recognizing the detection antibody was diluted 1: 5000 and added to the plate. The plate was allowed to react for 30 minutes at room temperature and washed five times with washing solution.
- To the plate was added tetramethyl benzidine (TMB) peroxidase substrate and peroxidase solution (BD555214, Franklin, NJ). Plates were allowed to react at room temperature for 4 minutes with regular shaking and shaken regularly. 2.5 MH 2 SO 4 was added as a reaction stopper and the absorbance was measured at 450 nm.
- TMB tetramethyl benzidine
- Purified isolated recombinant human APE1 / Ref-His was serially diluted within the range of 0-25 ng to obtain a standard curve showing linearity, and is shown in Table 1 and FIG. 1.
- the concentration of APE1 / Ref-1 protein in the serum of bladder cancer patients increased 1.5-3.5 times higher than in the serum of normal people.
- the APE1 / Ref-1 protein of the present invention can predict the diagnosis or prognosis of bladder cancer early, it can be usefully used as a marker for diagnosing bladder cancer.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
APE1/Ref-His의 농도(ng) | 흡광도 | 제로 표준값(zero standard subtracted) | ||
OD1 | OD2 | 평균값 | ||
0 | 0.0490 | 0.0480 | 0.0477 | 0.00 |
0.16 | 0.0530 | 0.0560 | 0.0543 | 0.01 |
0.8 | 0.0820 | 0.0810 | 0.0867 | 0.04 |
4 | 0.1940 | 0.2110 | 0.2083 | 0.12 |
20 | 0.5440 | 0.5110 | 0.5297 | 0.48 |
혈중 APE1/Ref-1 단백질의 농도(ng/100㎕) | |
정상인의 혈청 | 1.547±0.319 |
방광암 환자의 혈청 | 3.548±0.333 |
Claims (8)
- APE1/Ref-1을 함유하는 방광암 진단용 조성물.
- 제 1항에 있어서, 상기 APE1/Ref-1은 2기 이상의 방광암에 특이적인 것을 특징으로 하는 방광암 진단용 조성물.
- APE1/Ref-1에 특이적으로 결합하는 항체를 함유하는 방광암 진단 키트.
- 방광암 마커인 APE1/Ref-1에 특이적으로 결합하는 항체를 이용한 항원-항체 결합반응을 통해 생물학적 시료에서 APE1/Ref-1의 농도를 측정하는 방법.
- 제 4항에 있어서, 상기 생물학적 시료는 포유동물로부터 수득된 조직, 세포, 전혈, 혈청, 혈장, 타액, 객담 및 소변으로 이루어진 군으로부터 선택된 1종 이상을 포함하는 것을 특징으로 하는 APE1/Ref-1의 농도를 측정하는 방법.
- 제 4항에 있어서, 상기 항원-항체 결합반응은 효소면역분석법(ELISA), 방사능면역분석법(radioimmnoassay, RIA), 샌드위치 ELISA법, 웨스턴 블롯팅, 면역침강법, 면역조직화학염색법(immnohistochemical staining), 유체 세포 측정법(flow cytometry), 형광활성화 세포분류법(FACS), 효소기질발색법 및 항원-항체 응집법으로 이루어진 군으로부터 선택된 1종 이상의 방법을 이용하여 수행되는 것을 특징으로 하는 APE1/Ref-1의 농도를 측정하는 방법.
- 제 4항에 있어서, 상기 APE1/Ref-1의 농도는 정상인의 혈청에서보다 방광암 환자의 혈청에서 1.5~3.5배 높은 것을 특징으로 하는 APE1/Ref-1의 농도를 측정하는 방법.
- 제 4항에 있어서, 상기 APE1/Ref-1은 2기 이상의 방광암에 특이적인 것을 특징으로 하는 APE1/Ref-1의 농도를 측정하는 방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013541933A JP5857385B2 (ja) | 2010-12-08 | 2011-12-08 | Ape1/ref−1を含有する膀胱癌診断用組成物、及びこれを利用した膀胱癌診断キット |
US13/990,798 US8916354B2 (en) | 2010-12-08 | 2011-12-08 | Bladder cancer diagnosis composition containing APE1/Ref-1 and bladder cancer diagnostic kit using same |
CN2011800591773A CN103250055A (zh) | 2010-12-08 | 2011-12-08 | 含有ape1/ref-1的膀胱癌诊断用组合物及利用其的膀胱癌诊断仪 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0125086 | 2010-12-08 | ||
KR1020100125086A KR101251222B1 (ko) | 2010-12-08 | 2010-12-08 | APE1/Ref-1을 함유하는 방광암 진단용 조성물, 및 이를 이용한 방광암 진단 키트 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012077983A2 true WO2012077983A2 (ko) | 2012-06-14 |
WO2012077983A3 WO2012077983A3 (ko) | 2012-10-04 |
Family
ID=46207610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/009446 WO2012077983A2 (ko) | 2010-12-08 | 2011-12-08 | Ape1/ref-1을 함유하는 방광암 진단용 조성물, 및 이를 이용한 방광암 진단 키트 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8916354B2 (ko) |
JP (1) | JP5857385B2 (ko) |
KR (1) | KR101251222B1 (ko) |
CN (1) | CN103250055A (ko) |
WO (1) | WO2012077983A2 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2578502T3 (es) * | 2011-03-11 | 2016-07-27 | Roche Diagniostics Gmbh | APEX como marcador de la enfermedad pulmonar obstructiva crónica (EPOC) |
KR101514877B1 (ko) | 2013-05-06 | 2015-04-24 | 조선대학교산학협력단 | APE/Ref -1 및 JAG1/Notch의 대장암 진단용 마커로서의 용도 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030186338A1 (en) * | 2002-02-28 | 2003-10-02 | Deutsch Walter A. | Marker for diagnosing breast cancers and ovarian cancers |
JP2007314493A (ja) * | 2006-05-29 | 2007-12-06 | Kitasato Gakuen | モノクローナル抗体、その製造方法、及び用途 |
CA2681577A1 (en) * | 2007-03-23 | 2008-10-02 | F. Hoffmann-La Roche Ag | Apex as a marker for lung cancer |
CN101186930B (zh) * | 2007-10-09 | 2010-06-02 | 中国人民解放军第三军医大学第三附属医院 | 一种复制缺陷型重组腺病毒 |
US20100204299A1 (en) * | 2009-02-11 | 2010-08-12 | Daniel Regnier | C-cbl and antagonists thereof for the treatment and diagnosis of cancer |
CN101671394B (zh) * | 2009-04-24 | 2011-12-28 | 中国人民解放军第三军医大学第三附属医院 | 抗hAPE1蛋白的抗体及其制备方法与应用该抗体的试剂盒 |
-
2010
- 2010-12-08 KR KR1020100125086A patent/KR101251222B1/ko active IP Right Grant
-
2011
- 2011-12-08 US US13/990,798 patent/US8916354B2/en active Active
- 2011-12-08 WO PCT/KR2011/009446 patent/WO2012077983A2/ko active Application Filing
- 2011-12-08 JP JP2013541933A patent/JP5857385B2/ja active Active
- 2011-12-08 CN CN2011800591773A patent/CN103250055A/zh active Pending
Non-Patent Citations (4)
Title |
---|
GANGWAR, R. ET AL.: 'Influence of XPD and APE1 DNA repair gene polymorphism on bladder cancer susceptibility in north India' UROLOGY. vol. 73, no. 3, 28 November 2008, pages 675 - 680 * |
NARTER, K. F. ET AL.: 'Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1)' ANTICANCER RESEARCH. vol. 29, no. 4, April 2009, pages 1389 - 1393 * |
SAK, S. C. ET AL.: 'APE1 and XRCCl protein expression levels predicts cancer-specific survival following radical radiotherapy in bladder cancer' CLINICAL CANCER RESEARCH. vol. 11, no. 17, 01 September 2005, pages 6205 - 6211 * |
TERRY, P. D. ET AL.: 'APE1 genotype and risk of bladder cancer: evidence for effect modification by smoking' INTERNATIONAL JOURNAL OF CANCER. vol. 118, no. 12, 15 June 2006, pages 3170 - 3073 * |
Also Published As
Publication number | Publication date |
---|---|
KR20120063910A (ko) | 2012-06-18 |
US20130252255A1 (en) | 2013-09-26 |
US8916354B2 (en) | 2014-12-23 |
WO2012077983A3 (ko) | 2012-10-04 |
JP2014505859A (ja) | 2014-03-06 |
KR101251222B1 (ko) | 2013-04-08 |
JP5857385B2 (ja) | 2016-02-10 |
CN103250055A (zh) | 2013-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090030054A1 (en) | Cytoplasmic antigens for detection of candida | |
CA2554899C (en) | Method and kit for the measurement of neutrophil cell activation | |
NZ560978A (en) | Method for diagnosing multiple sclerosis using anti-GAGA antibodies | |
CA2502976A1 (en) | Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel | |
WO2010107158A1 (ko) | 티오레독신 1을 유효성분으로 하는 유방암 진단용 마커, 및 이를 이용한 유방암 진단 키트 | |
CN106053812A (zh) | 一种用于肝癌早期筛查和诊断的多种自身抗体联合检测elisa试剂盒 | |
CN110361547B (zh) | 一种化学发光定量检测粪便潜血的试剂及其检测方法和其在检测下消化道健康的用途 | |
WO2012091465A2 (ko) | 혈청 아밀로이드 a에 대한 단일클론항체 및 이를 생산하는 하이브리도마 세포 | |
CN110488025A (zh) | 一种化学发光定量检测粪便钙卫蛋白及其检测方法和其在肠道健康检测的用途 | |
EP1295127B1 (en) | Inter-alpha-trypsin as a marker for sepsis | |
US5552292A (en) | Method of screening for colorectal cancer | |
JP6193976B2 (ja) | バイオマーカーとしてのクロストリジウム・ディフィシル(Clostridiumdifficile)・デヒドロゲナーゼおよび毒素 | |
WO2012077983A2 (ko) | Ape1/ref-1을 함유하는 방광암 진단용 조성물, 및 이를 이용한 방광암 진단 키트 | |
CN111562395A (zh) | 一种胰腺癌肿瘤的标志物及其应用和试剂盒 | |
WO2017204295A1 (ja) | 消化器癌の判定方法 | |
WO2009062022A1 (en) | Methods and compositions for the diagnosis of crohn's disease | |
CN102971630A (zh) | 非酒精性脂肪性肝炎检测和/或鉴别用标记物、检测和/或鉴别非酒精性脂肪性肝炎的方法及用于它们的试剂盒 | |
WO2016195138A1 (ko) | Igm 반정량적 렙토스피라증 진단 키트 | |
EP2728358B1 (en) | Haptoglobin alpha-r as marker for diagnosing lung cancer | |
JPH0972906A (ja) | 腎・尿路系疾患の鑑別診断用キット | |
US20160349257A1 (en) | Methods and compositions for the diagnosis of crohn's disease | |
TWI789713B (zh) | 提升登革感染重症個體預測準確性之分群方法 | |
JP3569588B2 (ja) | 尿路感染症の診断用キット | |
RU2197736C1 (ru) | Реагент для иммуноферментного анализа и способ иммуноферментного тестирования специфических антител при описторхозе, вызываемом печеночной трематодой opisthorhis felineus | |
CN108387733A (zh) | 一种基于双分子荧光互补技术的mALB检测试剂盒、制备及使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11846569 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13990798 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2013541933 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11846569 Country of ref document: EP Kind code of ref document: A2 |